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Abstract
The faecal microbiota composition of infants born to mothers receiving intrapartum antibiotic
prophylaxis with ampicillin against group B Streptococcus was compared with that of con-
trol infants, at day 7 and 30 of life. Recruited newborns were both exclusive breastfed and
mixed fed, in order to also study the effect of dietary factors on the microbiota composition.
Massive parallel sequencing of the V3-V4 region of the 16S rRNA gene and qPCR analysis
were performed. Antibiotic prophylaxis caused the most marked changes on the microbiota
in breastfed infants, mainly resulting in a higher relative abundance of Enterobacteriaceae,
compared with control infants (52% vs. 14%, p = 0.044) and mixed-fed infants (52% vs.
16%, p = 0.13 NS) at day 7 and in a lower bacterial diversity compared to mixed-fed infants
and controls. Bifidobacteria were also particularly vulnerable and abundances were
reduced in breastfed (p = 0.001) and mixed-fed antibiotic treated groups compared to non-
treated groups. Reductions in bifidobacteria in antibiotic treated infants were also confirmed
by qPCR. By day 30, the bifidobacterial population recovered and abundances significantly
increased in both breastfed (p = 0.025) and mixed-fed (p = 0.013) antibiotic treated groups,
whereas Enterobacteriaceae abundances remained highest in the breastfed antibiotic
treated group (44%), compared with control infants (16%) and mixed-fed antibiotic treated
group (28%). This study has therefore demonstrated the short term consequences of mater-
nal intrapartum antibiotic prophylaxis on the infant faecal microbial population, particularly
in that of breastfed infants.
Introduction
Group B Streptococcus (GBS), a gram-positive commensal bacterium residing in the gastroin-
testinal and genitourinary tract of 10–30% of pregnant women, is the primary cause of early-
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onset bacterial sepsis in newborns, which represents a major cause of neonatal morbidity and
mortality [1]. The neonate can be exposed to GBS in utero, where the organism can reach the
amniotic fluid through ruptured membranes, and also during passage through the birth canal.
In addition to maternal colonization with GBS, other factors that increase the risk for early-
onset infection include prematurity, rupture of membranes or an intrapartum temperature
>37.5°C [2]. The introduction of universal GBS screening of all pregnant women in many
countries and subsequent intrapartum antibiotic prophylaxis (IAP) in GBS-positive women
has seen a significant reduction in early-onset GBS infection from 1.7 to 0.25 cases per 1,000
births in the United States [3].
While the use of IAP is clearly advantageous in the prevention of GBS infection, there is
uncertainty about its impact on the development of the infant gut microbiota. The first micro-
bial population the neonate encounters is the maternal vaginal and faecal microbiota, followed
by microorganisms from the external environment [4,5]. The early colonizers are facultative
anaerobes [6], whereas the establishment of a reducing environment permits the growth of
strict anaerobes, such as Bifidobacterium, Bacteroides and Clostridium. Microbial diversity and
richness continues to increase until the cessation of weaning when the microbiota becomes
similar to that of the adult [7–9]. It is well known that colonization in the early days after birth
is influenced by several factors including the mode of delivery (vaginal vs. caesarean section),
feeding choice (breast vs. formula feeding), gestational age (preterm vs. full-term), hospitaliza-
tion after birth and antibiotic use [10,11][12].
There are relatively few reports focusing on the possible effect that maternal IAP treatment
may have on the microbiota composition in infants [13,14]. The techniques used in previous
studies, such as plate counts, qPCR and PCR-DGGE, did not allow a complete analysis of the
entire faecal microbiota composition. Thus, the objective of this study was to use whole
genome sequencing in combination with qPCR to thoroughly examine the impact of maternal
IAP on the faecal microbiota composition during the first month of life. In addition, the effect
of dietary factors, i.e. exclusive breast-feeding versus mixed feeding, was also investigated.
Materials and Methods
Study design and samples collection
Ethical approval was received by the Comitato Etico Indipendente of S. Orsola-Malpighi Hos-
pital in Bologna (protocol 12/2013/U/Oss approved on March 12,2013). Twenty six infants
born at the Neonatal Intensive Care Unit, S. Orsola-Malpighi Hospital were recruited and
belonged to one of four groups: 1) BF-C, Breast-fed (BF) infants born to GBS negative mothers,
not receiving IAP before/at delivery (control); 2) BF-IAP, BF infants born to GBS positive, IAP
treated mothers; 3) MF-C, Mixed-fed (MF) infants born to GBS negative mothers (control); 4)
MF-IAP, MF infants born to GBS positive, IAP treated mothers (Table 1). Infants were born at
term by vaginal delivery, weighed between 2.5 and 4.0 kg at birth and did not receive any peri-
natal antibiotic or probiotic/prebiotic treatment. Written informed consent was obtained from
parent/legal guardian for participation in the study. Women who screened positive for GBS by
rectovaginal culture at 35–37 week gestational age were treated with intravenous ampicillin
(Amplital1) at labour every four hours until delivery (first dose 2g, following doses 1g each to
a maximum of 4g).
Faecal samples were collected from each infant during follow up visits at day 7 and 30 of
life. At each visit, information on weight gain, clinical conditions, feeding, and on-going treat-
ments (i.e. use of prebiotics, probiotics, antibiotics), were collected from the infants' parents.
After collection, faecal samples were immediately frozen at -80°C, until processing for bacterial
DNA extraction.
Infant Gut Microbiota and Intrapartum Antibiotic Prophylaxis
PLOS ONE | DOI:10.1371/journal.pone.0157527 June 22, 2016 2 / 11
Competing Interests: The authors have declared
that no competing interests exist.
DNA extraction from infant faecal samples
Total bacterial DNA was extracted from 200 mg of stool using the QIAamp DNA Stool Mini
Kit (Qiagen, West Sussex, UK), according to the manufacturer’s instructions with an additional
incubation at 95°C for 10 min with lysis buffer to improve the efficiency of bacterial cell rup-
ture for Gram-positive bacteria. Extracted DNA was stored at -80°C.
Preparation of 16S V3 and V4 rRNA amplicons for Illumina MiSeq
sequencing
Extracted DNA was processed to amplify and sequence the V3-V4 region of the 16S rRNA
gene [15]. These amplicons, approximately 550 bp in length, were generated using the forward
primer, 5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGC
AG-3’ and the reverse primer, 5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGG
ACTACHVGGGTATCTAATCC-3’. Each 25 μl PCR reaction contained 12.5 μl of HiFi Hot-
Start ReadyMix (KAPA Biosystems, Woburn, MA), 5 μl of each primer (0.2 μM) and microbial
DNA (5 ng/μl). PCR amplification was performed using the following program: heated lid at
110°C, 95°C for 3 min followed by 25 cycles at 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, fol-
lowed by a final elongation step at 72°C for 5 min. PCR products were cleaned using the
AMPure XP purification system (Beckman Coulter, UK). Illumina sequencing adapters and
dual-index barcodes were added to amplicons using the Nextera XT index kit (Illumina, San
Diego, CA). The following program was utilized for the second PCR amplification: 95°C for
3 min followed by 8 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 30 s and a final elonga-
tion at 72°C for 5 min. Amplicons were cleaned as outlined and quantified using the Qubit1
2.0 Fluorometer (Invitrogen, Life Technologies, CA, USA). The quantified libraries were
pooled equimolar to 4 nM prior to denaturation with 0.2N NaOH, further dilution with
hybridization buffer to 4pM and combined with 10% (v/v) denatured 4pM PhiX. Samples were
sequenced on the Illumina MiSeq platform at the Teagasc Food Research Centre facility using
a 2x300 nucleotide paired-end protocol.
Bioinformatic and statistical analysis
Raw sequence reads were assembled in to 300bp paired-ends using FLASH [16]. Reads were
further processed using the QIIME suite of tools, version 1.8.0 [17], including quality filtering
based on a quality score of>25 and removal of mismatched barcodes and sequences below
length thresholds. Denoising, chimera detection, and operational taxonomic unit (OTU)
grouping were performed using USEARCH v7 [17]. Taxonomic ranks were assigned to each
sequence by alignment of OTUs using PyNAST [18] to the SILVA SSURef database, release
111. Alpha and beta diversities were generated in QIIME using a rarefied OTU table and calcu-
lated based on weighted and unweighted Unifrac distance matrices [19]. Principal coordinate
Table 1. Characteristics of infants in the four groups of this study.
BF-IAP BF-C MF-IAP MF-C
No. of subjects 7 7 6 6
Gender (Female/Male) 2/5 2/5 4/2 5/1
Mode of Delivery SVD SVD SVD SVD
BF = exclusive breast-feeding
MF = a combination of formula (at least 50%) and breast milk feeding
SVD = Spontaneous vaginal delivery.
doi:10.1371/journal.pone.0157527.t001
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analysis (PCoA) plots were visualised using EMPeror v0.9.3-dev [20]. MiniTab release 17
(MiniTab Ltd. Coventry, UK) was used to perform statistical analysis. The nonparametric
Mann-Whitney analysis or Wilcoxon signed rank test were used to evaluate sample differences
in a pairwise manner. A corrected p-value of less than 0.05 was considered significantly
different.
Absolute quantification of total bacteria and bifidobacteria using
quantitative PCR (qPCR)
Total bacteria were quantified as described by Guo et al. (2008) [21] and Bifidobacterium breve
DSM 20213 as the reference strain. Bifidobacterium spp. were quantified as already described
[13]. Specificity for target organisms was evaluated using the BLASTN algorithm [22] and
melting curve analysis. Standard curves were established using 102 to 106 copies 16S rRNA/μl.
qPCR reactions were performed in triplicate in a StepOne RealTime PCR System (Applied Bio-
systems, Foster City, CA).
Results
Fecal microbiota composition of BF-IAP and BF-C fecal infants
The V3-V4 region of bacterial 16S rRNA gene was amplified and subjected to massive parallel
sequencing. A total of 11,109,005 raw sequences were obtained with an average of 217,823
reads per sample and were classified into 427 OTUs.
Alpha diversity analysis based on Chao1 (p = 0.0122), Simpson (p = 0.035), Shannon
(p = 0.0082) and observed species (p = 0.021) indices revealed significantly lower diversity in
BF-IAP infants compared with BF-C at day 7 (Fig 1). At day 30, the Chao1 index and observed
species increased in the BF-IAP infants, although this was not a significant increase, and the
Simpson and Shannon indices remained largely unchanged (S1 Fig).
At phylum level, Actinobacteria were not detected in the BF-IAP infants and were present
at 17% in control infants (p<0.001). BF-IAP infants had significantly higher abundances of
Proteobacteria (P<0.062) at day 7 compared to BF-C infants (Fig 2). BF-IAP infants were
dominated by genera belonging to the Enterobacteriaceae family (p = 0.044), particularly
Escherichia which accounted for 52% of the total relative abundance, compared with 14% in
the BF-C group (Fig 3). Bifidobacteria were not detected in any of the BF-IAP infants at day 7;
in contrast, Bifidobacterium represented 16% of the relative abundance of the microbiota from
BF-C infants (p = 0.001). BF-C infants also had higher levels of Bacteroides, 20% compared
with 7% in BF-IAP, although not statistically significant (p = 0.078) (Fig 3). By day 30, bifido-
bacteria numbers appeared to have recovered in the BF-IAP group and now account for 6% of
the relative abundance (p = 0.025) in both BF groups. Enterobacteriaceae continue to dominate
in BF-IAP infants, being detected at 44%, in contrast with 16% in BF-C. Additionally, at day 30
significantly higher levels of the Veillonellaceae family were detected in BF-C infants compared
with BF-IAP (p = 0.035) (S2 Fig).
Principal coordinate analysis (PCoA) plots constructed using unweighted UniFrac distance
matrices shows clear separation of BF-IAP samples from those of the BF-C infants at day 7, no
clear separation was observed at day 30, suggesting that microbial communities became more
uniform over time (Fig 4).
Fecal microbiota composition of MF-IAP and MF-C infants
No significant differences in diversity at day 7 was observed within mixed-fed infants, although
Chao1, Shannon and observed species indices were highest in the MF-C infants (Fig 1). By day
Infant Gut Microbiota and Intrapartum Antibiotic Prophylaxis
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30, alpha diversity was similar in both MF groups. MF-IAP infants contained higher abun-
dances of Proteobacteria, 37%, and Firmicutes, 41%, compared with MF-C infants, 17% and
29%, respectively, at day 7 (Fig 2). Actinobacteria (8%) and Bacteroidetes (36%) were highest
in the MF-C group compared with 1% and 21% in MF-IAP infants. MF-IAP infants contained
high abundances of organisms belonging to family Enterobacteriaceae, 35%, and Streptococcus,
32% (Fig 3), compared with 17% and 10% in the control group. MF-C infants had higher levels
of Bacteroides, 32%, and Bifidobacterium, 5%, compared with 13% and 1%, respectively, in
MF-IAP infants (Fig 3).
Fig 1. Estimates of alpha diversity for BF-IAP, BF-C, MF-IAP and MF-C samples at day 7.One outlier
has been identified in BF-IAP group regarding the evaluation of Simpson and Shannon indices, indicated with
a circle.
doi:10.1371/journal.pone.0157527.g001
Fig 2. Relative abundances of bacterial phyla in BF-IAP, BF-C, MF-IAP and MF-C faecal samples.
doi:10.1371/journal.pone.0157527.g002
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At day 30, Bacteroidetes were the dominant phylum in both groups, representing 26% in
control and 34% in IAP treated infants. Actinobacteria levels increased in the MF-IAP infants
to 7% and Firmicutes and Proteobacteria reduced to 30% and 28% respectively. At genus level,
the microbiota composition was more uniform than that at day 7. Members of the Enterobac-
teriaceae family fall to 28% and Streptococcus was significantly reduced to 8% (p = 0.042). The
Lachnospiraceae family, absent at day 7 in IAP treated infants, was detected at 4% at day 30.
Bifidobacteria significantly increased in MF-IAP infants from 0% at day 7 to 6% at day 30,
(p = 0.013) and remain highest in MF-C, 19%.
Moreover, Fig 3 shows that Veillonella is affected by the antibiotic treatment, as it does not
increase in the BF-IAP group between 7 and 30 days, whereas a strong increase is shown within
BF-C samples at the same sampling times (40%) and in BF-C samples with respect to BF-IAP
at 30 days (43%).
Principal coordinate analysis showed no clustering of samples from either MF-IAP or
MF-C groups at day 7 or 30 (data not shown).
Effects of dietary factors: comparison between BF-IAP and MF-IAP
infants
The gut microbiota of BF-IAP infants had lower diversity compared with the MF-IAP group
based on the Chao1, Simpson, Shannon and observed species indices, although not significant
(Fig 1). At day 30, diversity increased in the BF-IAP group although diversity indices remain
highest in the MF-IAP infants (S1 Fig).
At day 7, Actinobacteria were detected at 1% in MF-IAP and were absent in the BF-IAP
infants. The BF-IAP communities were dominated by Proteobacteria (54%) compared with
36% in MF-IAP, while MF-IAP had higher Bacteroidetes, 22%, compared with 7% in BF-IAP
(Fig 2). Firmicutes were similar in both groups (about 40%). Enterobacteriaceae were highest
in the BF-IAP group, in particular Escherichia were detected at 52% in BF-IAP compared with
14% in MF-IAP. BF-IAP infants were also found to have higher Veillonella, 22%, compared
with 4% in the MF-IAP group. Streptococcus were abundant in the MF-IAP infants 32% versus
12% in BF-IAP and Bacteroides were also highest in the MF-IAP group, 13%, compared with
6% in BF-IAP (Fig 3).
At day 30, Actinobacteria and Firmicutes abundances were similar in both groups, 6% and
29% in BF-IAP, and 7% and 30% in MF-IAP. Proteobacteria remained highest in BF-IAP, 44%,
Fig 3. Relative abundances of bacterial genera in BF-IAP, BF-C, MF-IAP and MF-C faecal samples.
Other category contains genera present at <1% of relative abundance.
doi:10.1371/journal.pone.0157527.g003
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compared with 28% in MF-IAP. Bacteroidetes increased in the BF-IAP to 21% and remain
highest in MF-IAP 34%. BF-IAP infants were found to have higher Veillonella then MF-IAP,
19% and 10%, respectively, and Escherichia, 33% and 16% (p = 0.04), respectively. MF-IAP
infants had higher Bacteroides, 22%, compared with 7% in the BF-IAP group. Bifidobacteria
were detected in both groups at 6%, showing a significant change from day 7 (BF-IAP
p = 0.025, MF-IAP p = 0.013). PCoA plots at day 7 show a separation of samples from BF-IAP
and MF-IAP, whereas no clear separation was observed at day 30 (Fig 4).
Absolute quantification of total bacteria and bifidobacteria via q-PCR
Fecal samples at day 7 and 30 of life from each group, BF-IAP, BF-C, MF-IAP and MF-C, were
subjected to qPCR analyses targeting total bacteria and bifidobacteria. Total bacteria numbers
were similar across the four groups, ranging between 9.38 to 9.71 at day 7 and 9.53 to 9.83 log
CFU/g at day 30, with no significant differences between groups observed (Fig 5A).
In the analysis of Bifidobacterium spp., numbers were observed to be significantly lower in
BF-IAP infants, 5.86 log CFU/g, compared with BF-C, 8.16 log CFU/g, at day 7 (p = 0.005) (Fig
Fig 4. Principal coordinates analysis (PCoA) of unweighted UniFrac distances. Percent of dataset variability explained by each principal coordinate is
shown in brackets in axis titles. Percent of dataset variability explained by each principal coordinate is shown in brackets in axis titles a) BF-IAP infants at day
7 in red, BF-C infants at day 7 in blue. b) BF-IAP infants at day 30 in red, BF-C infants at day 30 in blue. c) BF-IAP infants at day 7 in red, MF-IAP infants at
day 7 in blue. d) BF-IAP infants at day 30 in red, MF-IAP infants at day 30 in blue.
doi:10.1371/journal.pone.0157527.g004
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5B). Similar observations were made for MF-IAP infants, 5.81 log CFU/g, compared with 7.19
log CFU/g in MF-C infants (p = 0.03). At day 30, a significant increase was observed in both
BF-IAP and MF-IAP infants to 7.72 and 8.50 log CFU/g respectively (p = 0.035 and p = 0.036).
Numbers remain higher in BF-C infants, 8.62 log CFU/g, compared to 7.72 log CFU/g in BF-IAP
at day 30 but is no longer a significant difference. Numbers have significantly increased in MF-C
to 8.55 log CFU/g (p = 0.028) and are similar to that of MF-IAP infants, 8.50 log CFU/g.
Discussion
The use of antibiotics in early life is known to alter the commensal gut microbiota [7,23,24],
however, only few studies have focused on the effects of maternal intrapartum antibiotic
administration on the infant faecal microbiota. The investigators have previously found that
maternal IAP is responsible for a significant decrease in Bifidobacterium counts in exclusively
breast-fed, vaginally delivered infants at 7 days of life using qPCR [14]. The aim of the present
study, therefore, is to study microbial differences in further detail by analysing, for the first
time, the entire faecal microbiota composition in infants receiving or not receiving maternal
IAP by massive parallel sequencing and to see possible implications of antibiotic use during
labour. In addition, the microbiota of the same infants was analyzed at one month of age and
the influence of dietary factors was explored by including in the study mixed-fed newborns.
The analysis presented here shows that the faecal microbiota of BF-IAP infants was signifi-
cantly reduced in diversity and richness at day 7 with respect to BF-C infants. The most
marked differences were found within the Enterobacteriaceae family and the Bifidobacterium
genus, with numbers significantly higher and lower, respectively, in the BF-IAP group. These
observations are consistent with Edwards (2002) [25], whose study showed that IAP increased
exposure of neonates to ampicillin-resistant Enterobacteriaceae and Tanaka et al. (2009) [26],
who established an inverse relation between Enterobacteriaceae and Bifidobacterium counts
following antibiotic exposure in the early post-natal period. The bifidobacterial population
appear to have recovered in the BF-IAP day 30 samples, with a significant increase and relative
abundances quite similar to BF-C. On the contrary, Enterobacteriaceae remain highest in
BF-IAP infants. Massive parallel sequencing showed significant differences between MF-IAP
and MF-C infants at day 7, in particular regarding Actinobacteria and Bacteroides, which were
partially recovered at day 30. Recovery within the Bifidobacterium genus was also supported by
qPCR analysis. Veillonellamembers also appear to be strongly affected by IAP and this may
Fig 5. Box plots showing qPCR analysis of selectedmicrobial groups expressed in log CFU per gram of
faecal sample. Boxes show the median, 25th and 75th percentiles. Corrected p-values of < 0.05 and 0.01 are
denoted by * and **, respectively.
doi:10.1371/journal.pone.0157527.g005
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have consequences in the future development of the microbiota, considering that Veillonella is
known to be crucial for the gut microbiota development at an early stage [27] and it is involved
in the metabolism of lactic acid to short chain fatty acids, which are beneficial for colonocyte
health [28].
Dietary factors had a significant impact on the fecal microbiota composition, as shown by
the lower bacterial diversity and the lower species richness in the BF-IAP infants compared to
MF-IAP and the differences in the dominant microbial groups. A potential explanation is that
IAP exposure could alter the composition of the breast-milk microbiome which is known to be
rich in bifidobacteria and, consequently, microbial species transmission to the infant is modified
[29]. On the other hand, recent studies have outlined preliminary evidences of bifidobacteria
transmission from breast milk to the newborn [30]. Moreover, breastfed infants may absorb anti-
biotic molecules directly from breast milk leading to modifications in some microbial groups of
the intestinal microbiota, as already shown in the literature [27,31]. Our study also outlines that
Bifdobacterium abundances significantly increased in both BF andMF groups from day 30.
As previously outlined, this work has shown that one of the main implication of antibiotic
use during labour is the increase in Enterobacteriaceae which may cause infections and gut
problems in neonates [32]. Therefore, intervention strategies to be applied in the early stage of
life in order to re-equilibrate the gut microbiota composition are envisaged. The use of probiot-
ics, in particular bifidobacteria, can be one of them, as also shown by studies performed by sev-
eral authors [33–35].
In conclusion, massive sequencing used for the first time to characterize the entire faecal
microbial population in infants exposed to maternal IAP has shown that the antibiotic prophy-
laxis has a significant impact on the early fecal microbial composition of infants, which par-
tially recovers after 30 days of life, in particular for some microbial groups such as
Bifidobacterium spp. Moreover, the initial effect of IAP in term of reduced biodiversity and
bifidobacteria counts is greater in BF infants than MF ones. Further studies analysing the vagi-
nal, breast-milk and faecal microbiota from pregnant women and their infants might provide
new insights into the effects of IAP exposure.
Supporting Information
S1 Fig. Evaluation of alpha diversity. Estimates of alpha diversity for faecal samples from
BF-IAP, BF-C, MF-IAP cohorts at day 30.
(TIF)
S2 Fig. Abundance of bacterial families. Relative abundances of bacterial families in BF-IAP,
BF-C, MF-IAP and MF-C faecal samples. The Other category contains all other families pres-
ent at<1% of relative abundance. Black and white colour in print is required.
(TIF)
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